Quality & compliance
We are designing the quality and regulatory foundation for a future multi-brand platform. The priorities below describe systems to be established, not a fully implemented operating model.
The current focus is team formation, acquisition screening and defining platform requirements. This site does not disclose completed acquisitions, an operating SKU portfolio, a selected QMS or contracted manufacturers. Diligence will assess each target’s controls and history; after a transaction, a risk-based integration plan will define owners, priorities and verification milestones.
The intended model will separate quality decisions from short-term sales pressures. Quality and regulatory leadership will define approval, hold, release and escalation responsibilities with the acquired businesses. Quality agreements will document the platform’s and manufacturers’ respective responsibilities; contracting production will not remove either party’s applicable obligations.
Before onboarding, the proposed process will assess ingredient suppliers and manufacturing sites against product risk, capability, relevant inspection and audit findings, specifications and corrective-action records. Written quality agreements, change notifications, periodic reviews and follow-up audits will guide continuing oversight. These are selection and integration criteria, not an announcement of approved suppliers.
For each product and facility, the future team will determine applicable CGMP and food-safety requirements, assess biological, chemical and physical hazards, and review the controls needed to address them. Where required, qualified personnel will oversee food-safety plans, preventive controls, monitoring, verification and related records. Applicability and any exemptions will be assessed rather than assumed.
The planned framework will establish controlled ingredient, formulation, packaging and finished-product specifications. Sampling and testing will reflect product and process risks, supported by suitable methods and laboratory capability. Release responsibilities, required records, deviations and shipment holds will be defined before platform release controls are relied upon; testing will support, rather than replace, process controls.
The system will be built around applicable FDA requirements under the FD&C Act, including animal-food labeling under 21 CFR Part 501 and applicable CGMP, hazard-analysis and risk-based preventive-control requirements under Part 507. Reviews will also address registration and labeling requirements in the states of sale and relevant AAFCO Model Regulations. AAFCO itself is not a regulator and does not approve, certify or endorse pet foods or individual company labels.
All external claims will require scientific-evidence and regulatory-applicability review, including labels, websites and other promotional materials. Proposed joint, digestive, skin and coat, oral and senior nutrition areas are development directions, not efficacy claims. Disease-treatment, mitigation or prevention claims, or structure/function claims beyond food purposes, may raise animal-drug issues and will require separate assessment before use.
As the first brands join, the company will establish a common traceability framework for core SKUs, linking formula versions, ingredient lots, production batches, distribution, inventory and complaint records. Existing brand systems will first be assessed; integration priorities, data ownership and trace exercises will then be defined. No specific QMS or live platform-wide traceability system is represented here.
The planned process will define complaint intake, risk triage, investigation, escalation, shipment holds, notification and recall coordination. The team will review acquired brands’ incident and recall histories during diligence and develop response roles and exercises with relevant partners. This page makes no assertion about an acquired portfolio’s recall history or demonstrated recall performance.
The intended corrective and preventive action (CAPA) process will connect deviations and complaints to root-cause analysis, assigned actions and effectiveness checks. Changes to suppliers, formulas, specifications, processes and labels will require documented impact assessment and approval. Management reviews will track unresolved risks and integration progress as the quality system develops.
Whether production is owned or contracted, we will retain our own quality governance responsibilities.
A shared ambition
Join people who want to build brands, teams and operating capability from the ground up.
Get in touch